Quality of life in patients with limited (1–3) brain metastases undergoing stereotactic or whole brain radiotherapy

• Published in: Strahlentherapie und Onkologie 2020-01, Vol.196 (1), p.48-57
• Main Authors: Steinmann Diana PD Dr Dr, Vordermark Dirk, Gerstenberg Wiebke, Aschoff Raimund, Gharbi, Nadine, Müller Axel, Schäfer Christof, Theodorou Marilena, Wypior Hans-Joachim, Geinitz Hans
• Format: Article
• Language: English
• Subjects: Brain; Brain cancer; Decision making; Metastasis; Nausea; Quality of life; Radiation therapy; Subgroups; Toxicity
• ISSN: 0179-7158; 1439-099X
• DOI: 10.1007/s00066-019-01506-w

PurposePublished results of quality of life (QoL) studies mostly concern whole brain radiotherapy for limited or multiple brain metastases. This prospective multicentre study was designed to compare the QoL of patients with limited (1–3) brain metastases treated with either whole brain (WBRT) or stereotactic radiotherapy (SRT).MethodsFrom 01/2007–03/2011, 90 limited brain metastases patients who were previously untreated (n = 77) or had undergone primary surgery (n = 13) were recruited at 14 centres in Germany and Austria. QoL was measured with the EORTC-QLQ-C15-PAL and BN20 brain modules before the start of radiotherapy and after 3 months.ResultsFifty-two patients (58%) received WBRT and 38 (42%) received SRT. At 3 months, 67 patients (74%) were still living, and 92.6% of the 3‑month survivors completed the second set of questionnaires. Analysis of the QLQ-C15-PAL and BN20 scales revealed significant deterioration in patients treated with WBRT and SRT in physical function (p